Pfizer expects to rake in sales of $ 15 billion from the Covid-19 vaccine this year

by

His fourth-quarter earnings report was the first since the vacant Pfizer Covid-19 received an emergency use permit from the U.S. Food and Drug Administration in December – the first vaccine to receive such a license. Since then, the vaccine, developed in partnership with the German company BioNTech, has begun to spread across the country, as well as elsewhere around the world.
Pfizer (PFE) he said he has sent 65 million doses to date, including 29 million to the United States. The company expects to deliver 200 million doses to the United States by the end of May.

The company raised its overall earnings guidance for 2021 to between $ 3.10 and $ 3.20 per share, thanks in part to expected revenue contributions from the vaccine.

The forecast was a clear feature of a mixed employment report. Pfizer posted quarterly revenues of nearly $ 11.7 billion, up 12% from the same period a year earlier and slightly ahead of Wall Street analysts ’projections. Earnings per share hit $ 0.42, but fell short of Wall Street expectations. The company’s stock fell nearly 3% in early trading on Tuesday.

“2020 has been a year of transformation, not only for Pfizer, but also in the lives of every patient in every community we serve,” Pfizer CEO Albert Bourla said in a statement. “We have seen the end of Pfizer’s ten-year transformation into a true play, science and innovation company … Our remarkable success in developing a vaccine against COVID-19, together with our partner BioNTech , just one example of what we believe this new Pfizer is capable of achieving. “

.Source